Rene-olivier O. Casasnovas

Dijon, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Journal: Haematologica
Published: November 06, 2025

Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.

Journal: Blood advances
Published: August 11, 2025

Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Journal: Blood advances
Published: April 16, 2025

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.

Journal: Blood
Published: February 18, 2025

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Journal: Blood advances
Published: December 10, 2024

PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction.

PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction.

Journal: Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
Published: September 12, 2024

How to treat advanced Hodgkin lymphoma?

How to treat advanced Hodgkin lymphoma?

Journal: Current opinion in oncology
Published: July 15, 2024

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.

Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.

Journal: Journal of hematology & oncology
Published: May 06, 2024

Treatment Strategies in Advanced-Stage Hodgkin Lymphoma.

Treatment Strategies in Advanced-Stage Hodgkin Lymphoma.

Journal: Cancers
Published: April 08, 2024

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 16, 2024

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.

Journal: The Lancet. Haematology
Published: January 23, 2024

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.

Journal: Haematologica
Published: August 14, 2023
Showing 1-12 of 78

Last Updated: 09/26/2026